Celon Pharma SA (CLN) Stock Statistics & Valuation Metrics

Celon Pharma SA has a market cap or net worth of zł1.15B. The enterprise value is zł1.15B.

Celon Pharma SA has 53,856,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Celon Pharma SA’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -14.09%.

The current PE Ratio of Celon Pharma SA is ―. Celon Pharma SA’s PEG ratio is -0.11.

In the last 12 months, Celon Pharma SA had revenue of 209.80M and earned -79.36M in profits. Earnings per share was -1.47.

In the last 12 months, operating cash flow was 23.86M and capital expenditures -54.44M, giving a free cash flow of -30.58M billion.

Celon Pharma SA pays an annual dividend of zł0.298, resulting in a dividend yield of 0.43%

Celon Pharma SA upcoming earnings date is May 27, 2026, TBA (Confirmed).

Celon Pharma SA as a current ratio of 1.62, with Debt / Equity ratio of 5.21%

In the past 12 months, Celon Pharma SA has paid 20.40M in taxes.

Celon Pharma SA EV to EBITDA ratio is -104.55, with an EV/FCF ratio of -35.84.

Celon Pharma SA has zł19.91M in cash and marketable securities with zł18.94M in debt, giving a net cash position of zł966.00K billion.

Gross margin is 45.75%, with operating margin of -27.06%, and net profit margin of -37.83%.

The average price target for Celon Pharma SA is ―, which is 11.43% higher than the current price. The consensus rating is ―